Campaign

CRO#: 612186

Epitheal

Pharma

Epitheal Limited has developed a patent-pending compound for treating skin damage and disease, which will be available over the counter and without a prescription.
by John Prendergast
Galway
98% Funded
€ 400,000 Funding goal
€ 393,412 Invested
79Investors


Company Summary :

 

 

Epitheal’s patent-pending compound is a natural product, requiring no prescription and delivers faster superior skin-healing results described as ‘gold dust’ in the industry.

 

Key highlights:

  • Initial commercial focus is on the equine healthcare market is driven by Ireland’s strong international reputation and an attractive growth rate of 6.8% CAGR to 2030, reaching a value of $2.3 billion globally.
  • Company already has established laboratory facilities and premises. 
  • Extensive R&D conducted; incl. Safety & efficacy clinical trials completed, field trials completed. 
  • Irish Government & EU funding approved (€250k) via Udaras Na Gaeltachta. 
  • Presently seeking medicines approval to enter the veterinary markets Q4, 2025 and the human medicines market 2027.